The issue received bids of 13,84,72,771 equity shares against the offered 97,50,482 equity shares
FinTech BizNews Service
19 October, Mumbai: The Initial Public Offering of Sahajanand Medical Technologies Limited was subscribed 14.20 times on the final day of bidding.
Qualified Institutional Buyers (QIB) portion subscribed 34.70 times. Non institutional investors and Retail Portion were subscribed 14.64 times and 3.03 times, respectively. Employee Reserved portion subscribed 0.37 times.
Incorporated in 1999, the company is a Class III and Class C/D medical devices company with a portfolio of technologically advanced medical devices across vascular and structural heart intervention. According to a F&S Report, the company is the first in the world to receive a CE certification for a DES with a biodegradable polymer- based paclitaxel-eluting stent (Infinnium). Over the years, the company has introduced several innovative products, driven by its focus on research and development and precision manufacturing capabilities enabling it to deliver quality products backed by clinical data, with a presence across 65 countries including India in the three months ended June 30, 2026 and 77 countries including India in Fiscal 2026.
It is a R&D driven company engaged in the development of Class III and Class C/D medical devices, with an emphasis on vascular intervention (VI) and structural heart (SH). Its portfolio of VI products includes coronary intervention products such as coronary stents and coronary balloons, SH products include TAVI and occluders, and others including its own brand of renal stents, peripheral DCBs and other trading products.
